| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 |
| filingDate |
2017-02-04^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-05-02^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102393281-B1 |
| titleOfInvention |
TLR7 agonist trifluoroacetate salt and its crystalline form B, preparation and use |
| abstract |
The present invention relates to a TLR7 agonist, 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)-benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine (Formula I ), crystalline Form B of trifluoroacetate, a process for preparing said trifluoroacetate and crystalline Form B, and use of said trifluoroacetate and crystalline Form B. |
| priorityDate |
2016-02-05^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |